Phase Ii study of mitolactol in chemotherapy-refractory metastatic breast cancer
Creech, R.H.; Catalano, R.B.; Dierks, K.M.; Shah, M.K.
Cancer Treatment Reports 68(12): 1499-1501
1984
ISSN/ISBN: 0361-5960 PMID: 6548936 Document Number: 240252
Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. Only one patient, with nodal and chest wall metastases, had a sustained complete regression; two patients had stable disease; and 35 patients had disease progression. The toxicity, which was primarily hematologic, was acceptable.
Document emailed within 1 workday
Related Documents
Halim, A.; Wahba, H. 2012: Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study Journal of BUON: Official Journal of the Balkan Union of Oncology 17(2): 254-258Creagan, E.T.; Ahmann, D.L.; Schutt, A.J.; Green, S.J. 1982: Phase Ii study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma Cancer Treatment Reports 66(6): 1425-1426
Medina, W.; Kirkwood, J.M. 1982: Phase Ii trial of mitolactol in patients with metastatic melanoma Cancer Treatment Reports 66(1): 195-196
Amrein, P.C.; Coleman, M.; Richards, F.; Poulin, R.F.; Bernhardt, B.; Ginsberg, S.J.; Green, M.R.; Morrison, A.; Cortes, E.; Kiang, D.; Weinberg, V.; Wood, W.C. 1982: Phase Ii study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study Cancer Treatment Reports 66(5): 1211-1213
Carpenter, J.T.; Raney, M.; Logan, T. 1986: Phase Ii evaluation of procarbazine in metastatic breast cancer: a Southeastern Cancer Study Group Trial Cancer Treatment Reports 70(5): 679-680
Muthalib, A.; Darwis, I.; Prayogo, N.; Sutjipto 2000: Preliminary results of multicenter phase Ii trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 498-504
Chitapanarux, I.; Tonusin, A.; Sukthomya, V.; Charuchinda, C.; Pukanhapan, N.; Lorvidhaya, V. 2003: Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer Gynecologic Oncology 89(3): 402-407
Kulke, M.H.; Demetri, G.D.; Sharpless, N.E.; Ryan, D.P.; Shivdasani, R.; Clark, J.S.; Spiegelman, B.M.; Kim, H.; Mayer, R.J.; Fuchs, C.S. 2002: A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer Cancer Journal 8(5): 395-399
Shinagawa, K.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Mukaiyama, T.; Fukutani, H.; Tabata, M.; Hirano, A.; Mizunuma, N. 1989: A study of complete responders in cases of metastatic breast cancer treated with combination chemotherapy Gan no Rinsho. Japan Journal of Cancer Clinics 35(5): 581-586
Koyama, H.; Iesato, A.; Fukushima, Y.; Okada, T.; Watanabe, T.; Harada, M.; Ito, T.; Maeno, K.; Mochizuki, Y.; Ito, K.; Amano, J. 2011: A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1123-1126
Lück, H.J.; Thomssen, C.; du Bois, A.; Lisboa, B.W.; Untch, M.; Kühnle, H.; Jänicke, F.; Meerpohl, H.G.; Lindner, C.; Konecny, G.; Hecker, D.; Diergarten, K. 1997: Preliminary results of a phase Ii study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer Seminars in Oncology 24(1 Suppl 3: S13-S16
Pannuti, F.; Rossi, A.P.; Di Marco, A.R.; Fruet, F.; Lelli, G.; Strocchi, E.; Rocchetta, G.; Piana, E.; Martoni, A. 1981: Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot study Panminerva Medica 23(1): 25-28
Pedrazzoli, P.; Zamagni, C.; Martoni, A.; Capotorto, A.M.; Da Prada, G.A.; Pavesi, L.; Preti, P.; Lelli, G.; Pannuti, F.; Robustelli della Cuna, G. 1994: Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study Tumori 80(4): 273-275
Slee, P.H.T.J.; Rodenburg, C.J.; Nortier, J.W.R.; van Bochove, A. 2004: A phase i dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer Netherlands Journal of Medicine 62(9): 314-319
Stewart, J.A. 1988: Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists Seminars in Oncology 15(2 Suppl. 2): 10-16
Stemmler, H.J.; Salat, C.; Lindhofer, H.; Menzel, H.; Untch, M.; Kahlert, S.; Konecny, G.; Sauer, H.; Ledderose, G.; Heinemann, V.; Kolb, H.J. 2005: Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study Anticancer Research 25(4): 3047-3054
Li, J.; Xu, J-Ming.; Li, J.; Zhang, X-Dong.; Bai, Y.; Chu, Y-Ping.; Wang, Y-Hua.; Liu, D-Qi.; Jin, M-Lin.; Shen, L. 2008: Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer Zhonghua Zhong Liu Za Zhi 30(3): 225-227
Nichols, W.C.; Kvols, L.K.; Ingle, J.N.; Edmonson, J.H.; Ahmann, D.L.; Rubin, J.; O'Connell, M.J. 1978: Phase Ii study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy Cancer Treatment Reports 62(5): 837-839
Jiang, Z.F.; Xu, F.R.; Fan, J.; Li, B.J.; Gao, J.N.; Hu, J.W.; Wang, X.J.; Zhang, Y.Q.; Wang, J.H.; Li, F.; Liu, Q.; Liu, Y.H.; Wang, S.; Wang, Y.S.; Ouyang, Q.C.; Hu, B.; Sun, G.P.; Zhang, Y.; Zang, A.M.; Fan, P.Z.; Wu, C.P.; Liu, J.; Zhang, H.W.; Wang, W.; Hu, X.C.; Tang, L.L.; Zhang, J.; Bao, Y.Y.; Geng, C.Z.; Sun, Q.; Zhang, F.; Yin, Y.M.; Jiang, H.C.; An, Y.H. 2018: A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer Zhonghua Yi Xue Za Zhi 98(16): 1231-1235
Rahman, Z.; Champlin, R.; Rondon, G.; Frye, D.; Valero, V.; Mehra, R.; Hortobagyi, G. 1997: Phase I/Ii study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer Seminars in Oncology 24(5 Suppl 17: S17